Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3221182 | 0.80 | CYP3A4 (0.44) | CYP3A4ALOX15CYP19A1CFTRGOPC | |
| SCHEMBL28140395 | 0.69 | CYP3A4 (0.47) | CYP3A4ALOX15CYP19A1CFTRGOPC | |
| SCHEMBL6239972 | 0.68 | CYP19A1 (0.42) | CYP3A4ALOX15CYP19A1CYP2C9MAPT | |
| SCHEMBL27677963 | 0.67 | CYP3A4 (0.42) | CYP3A4ALOX15CYP19A1CFTRGOPC | |
| SCHEMBL14957411 | 0.66 | CFTR (0.43) | CYP3A4ALOX15CYP19A1CFTRGOPC | |
| SCHEMBL27866152 | 0.65 | CYP3A4 (0.46) | CYP3A4ALOX15CYP19A1CYP2C9TP53 | |
| SCHEMBL29130441 | 0.64 | CASP6 (0.45) | CYP3A4ALOX15CYP19A1CFTRGOPC | |
| SCHEMBL3289417 | 0.64 | CYP3A4 (0.42) | CYP3A4ALOX15CYP19A1CFTRGOPC | |
| SCHEMBL8756989 | 0.64 | CYP19A1 (0.41) | CYP3A4ALOX15CYP19A1CFTRGOPC | |
| SCHEMBL28459231 | 0.63 | SMN1; SMN2 (0.46) | CYP3A4ALOX15SMN1; SMN2CYP2C9GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210022305-A1 | A HUMULUS PLANT VARIANT AND EXTRACTS THEREOF | BOMI, LLC | 2021-01-28 | — | — | US | disclosed |
| EP-3765000-A1 | A HUMULUS PLANT VARIANT AND EXTRACTS THEREOF | BOMI, LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019178103-A1 | A HUMULUS PLANT VARIANT AND EXTRACTS THEREOF | Bomi LLC (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2012007725-A2 | METHOD OF REPROGRAMMING A CELL | PLASTICELL LTD (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-7749962-B2 | Alpha 5 beta 1 and its ability to regulate the cell survival pathway | UNIVERSITY OF MEDICINE & DENTISTRY OF NJ (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1827445-A2 | ENHANCING TREATMENT OF CANCER AND HIF-1 MEDIATED DISODERS WITH ADENOSINE A3 RECEPTOR ANTAGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1539247-A4 | ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATHWAY | UNIV NEW JERSEY MED (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007040565-A9 | ENHANCING TREATMENT OF CANCER AND HIF-1 MEDIATED DISODERS WITH ADENOSINE A3 RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RES & DEV (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007040565-A2 | ENHANCING TREATMENT OF CANCER AND HIF-1 MEDIATED DISODERS WITH ADENOSINE A3 RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1420778-B1 | USE OF MEK INHIBITORS FOR TREATING VIRUS INDUCED HEMORRHAGIC SHOCK OR FEVER | BEVEC DORIAN (DE) | 2006-11-22 | — | — | EP | disclosed |
| EP-1539247-A2 | ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATHWAY | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050119289-A1 | Enhancing treatment of MDR cancer with adenosine A3 antagonists | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. | 2005-06-02 | — | — | US | disclosed |
| EP-1515719-A2 | ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A3 ANTAGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004043340-A2 | ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATHWAY | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040067932-A1 | Enhancing treatment of MDR cancer with adenosine A3 antagonists | CREDIT SUISSE AG | 2004-04-08 | — | — | US | disclosed |
| WO-2004000237-A2 | ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A3 ANTAGONISTS | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000224-A2 | ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A3 ANTAGONISTS | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-1259232-A1 | METHOD FOR IDENTIFYING AN AGENT FOR TREATMENT OF NIDDMDIABETES BY INTERACTION WITH COMPOUND U0126 | BIOVITRUM AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001064209-A1 | METHOD FOR IDENTIFYING AN AGENT FOR TREATMENT OF NIDDMDIABETES BY INTERACTION WITH COMPOUND U0126 | BIOVITRUM AB (SE) | 2001-09-07 | — | — | WO | disclosed |
| US-20010019832-A1 | Methods for identification using U0126 | BIOVITRUM AB (SE) | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067932-A1 | Enhancing treatment of MDR cancer with adenosine A3 antagonists | ADORA3, ADORA2A, ABCC3 | CYP3A4 1576/4885ALOX15 4294/4885CYP19A1 2877/4885 |
| US-20210022305-A1 | A HUMULUS PLANT VARIANT AND EXTRACTS THEREOF | CNR2, CNR1, FAAH | CYP3A4 233/4885ALOX15 131/4885CYP19A1 372/4885 |
| US-20050119289-A1 | Enhancing treatment of MDR cancer with adenosine A3 antagonists | ADORA3, ADORA2A, ABCB1 | CYP3A4 1524/4885ALOX15 4391/4885CYP19A1 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.